Obesity impacts effectiveness of arthritis treatments

New medical research indicates that obesity significantly impacts the effectiveness of treatments for inflammatory joint diseases. An individual patient data meta-analysis of 16 phase 3 randomized trials involving 11,883 participants found that a higher body mass index (BMI) reduces the efficacy of JAK inhibitors in treating rheumatoid arthritis. The study showed that as BMI increases, the relative risk for a 20% improvement in response decreases, with class 2 obesity showing a notably lower response rate compared to those at a healthy weight.

In a separate observational study focusing on psoriatic arthritis (PsA), researchers found that addressing obesity may improve outcomes when combined with standard treatments. Patients with PsA and obesity who used the weight management medication tirzepatide concurrently with biologic therapy showed greater improvements in clinical, physical function, and skin disease measures than those receiving biologic therapy alone. Nearly half of the patients in the combination group achieved a patient-acceptable symptom state, compared to approximately one-fifth of those receiving only biologics.